RFX5

From Wikipedia, the free encyclopedia
Regulatory factor X, 5 (influences HLA class II expression)
Available structures
PDB Ortholog search: PDBe, RCSB
Identifiers
SymbolRFX5
External IDsOMIM: 601863 MGI: 1858421 HomoloGene: 388 GeneCards: RFX5 Gene
RNA expression pattern
More reference expression data
Orthologs
SpeciesHumanMouse
Entrez599353970
EnsemblENSG00000143390ENSMUSG00000005774
UniProtP48382Q9JL61
RefSeq (mRNA)NM_000449NM_017395
RefSeq (protein)NP_000440NP_059091
Location (UCSC)Chr 1:
151.31 – 151.32 Mb
Chr 3:
94.95 – 94.96 Mb
PubMed search

DNA-binding protein RFX5 is a protein that in humans is encoded by the RFX5 gene.[1][2]

A lack of MHC-II expression results in a severe immunodeficiency syndrome called MHC-II deficiency, or the bare lymphocyte syndrome (BLS; MIM 209920). At least 4 complementation groups have been identified in B-cell lines established from patients with BLS. The molecular defects in complementation groups B, C, and D all lead to a deficiency in RFX, a nuclear protein complex that binds to the X box of MHC-II promoters. The lack of RFX binding activity in complementation group C results from mutations in the RFX5 gene encoding the 75-kD subunit of RFX (Steimle et al., 1995). RFX5 is the fifth member of the growing family of DNA-binding proteins sharing a novel and highly characteristic DNA-binding domain called the RFX motif. Multiple alternatively spliced transcript variants have been found but the full-length natures of only two have been determined.[2]

Interactions

RFX5 has been shown to interact with CIITA.[3][4]

References

  1. Villard J, Reith W, Barras E, Gos A, Morris MA, Antonarakis SE, Van den Elsen PJ, Mach B (January 1998). "Analysis of mutations and chromosomal localisation of the gene encoding RFX5, a novel transcription factor affected in major histocompatibility complex class II deficiency". Hum Mutat 10 (6): 430–5. doi:10.1002/(SICI)1098-1004(1997)10:6<430::AID-HUMU3>3.0.CO;2-H. PMID 9401005. 
  2. 2.0 2.1 "Entrez Gene: RFX5 regulatory factor X, 5 (influences HLA class II expression)". 
  3. Hake, S B; Masternak K, Kammerbauer C, Janzen C, Reith W, Steimle V (October 2000). "CIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation". Mol. Cell. Biol. (UNITED STATES) 20 (20): 7716–25. doi:10.1128/MCB.20.20.7716-7725.2000. ISSN 0270-7306. PMC 86349. PMID 11003667. 
  4. Scholl, T; Mahanta S K, Strominger J L (June 1997). "Specific complex formation between the type II bare lymphocyte syndrome-associated transactivators CIITA and RFX5". Proc. Natl. Acad. Sci. U.S.A. (UNITED STATES) 94 (12): 6330–4. doi:10.1073/pnas.94.12.6330. ISSN 0027-8424. PMC 21049. PMID 9177217. 

Further reading

External links

This article incorporates text from the United States National Library of Medicine, which is in the public domain.


This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.